Abid Hussain

Dr Abid Hussain

Research Associate

Future Industries Institute

Future Industries Institute

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

Dr Abid Hussain is an emerging research leader in drug delivery and RNA therapeutics, with a Ph.D. in Pharmaceutical Sciences (2019) and a strong track record spanning both industry and academia. His expertise lies in the design and development of lipid-based nanoparticles for targeted delivery of mRNA and siRNA to treat cancer, cardiovascular, respiratory viral infection and metabolic diseases.
As a former Formulation Manager in a leading pharmaceutical company (2019-2021), Dr Hussain led multiple inhalation-based formulation projects, contributing to three internationally patented technologies (WIPO/PCT) and playing a pivotal role in the successful submission of two drug products to the European Medicines Agency (EMA) between 2020–2021.
After transitioning back to academia in 2021, Dr Hussain has made significant contribution to the field of drug delivery technologies, with a more specific recent focus on mRNA therapeutics. As an early career researcher, he has published 29 peer-reviewed articles including in Nature Communications (IF 14.7), Science Advances (IF 14.0), Signal Transduction and Targeted Therapy (IF 40.8), Bioactive Materials (IF 18), Journal of Controlled Release (IF 10.5), Nano Letters (IF 9.6), Plos Pathogen (IF 5.5), Biomaterials Science (5.8), Nano Research (IF 9.6), Molecular Therapy (IF 12.1), and Journal of Nanobiotechnology (10.6). His publications have received over 1250 citations and h-index is 19 (i10-index of 27) (accumulated IF of 250+).
A recent highlight is his recent first authorship publication in Nature Communication (2024) reporting the development of a lipid-based formulation for the delivery of mRNA for the treatment of Hyperuricemia and Gout. This work has significant translational potential and underscores the transformative potential of mRNA therapeutics in addressing metabolic disorders.
His experience working in multidisciplinary teams ideally positions him to contribute significant advances in the RNA therapeutic field. Under the mentoring of Prof Thierry and in collaboration with experts in heart failure (Baker Inst), pancreatic cancer (Garvan Inst) and lung disease (University of Adelaide), Dr Hussain currently leads an innovative research program on targeted lipid nanoparticles for organ-specific RNA delivery, offering possible treatments for cardiovascular diseases, cancer and respiratory viral infection.

Leading projects on optimizing and developing ligand conjugated LNPs for delivery functional mRNA for the treatment of Pancreatic Cancer, Heart Failure by collaborating with Baker Institute and Garvin Institute experts.

Strong collaboration with Cystic Fibrosis Research Group at the University of Adelaide, Dr Hussain is working to develop ligand Conjugated LNPs specifically for pulmonary delivery.

Year Citation
2024 Zhang, M., Hussain, A., Hu, B., Yang, H., Li, C., Guo, S., . . . Huang, Y. (2024). Atavistic strategy for the treatment of hyperuricemia via ionizable liposomal mRNA. Nature Communications, 15(1), 1-16.
DOI
2023 Hu, B., Kong, S., Weng, Y., Zhao, D., Hussain, A., Jiao, Q., . . . Huang, Y. (2023). Lipid-conjugated siRNA hitchhikes endogenous albumin for tumor immunotherapy. Chinese Chemical Letters, 34(11, article no. 108210), 1-7.
DOI
2023 Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X. J., & Huang, Y. (2023). mRNA-based modalities for infectious disease management. Nano Research, 16(1), 672-691.
DOI
2022 Tuguntaev, R. G., Hussain, A., Fu, C., Chen, H., Tao, Y., Huang, Y., . . . Guo, W. (2022). Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations. Journal of Nanobiotechnology, 20(1, article no. 236), 1-31.
DOI
2022 Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M., . . . Huang, Y. (2022). mRNA vaccines for COVID-19 and diverse diseases. Journal of Controlled Release, 345, 314-333.
DOI
2022 Yu, C., Li, K., Xu, L., Li, B., Li, C., Guo, S., . . . Liang, X. J. (2022). siRNA-functionalized lanthanide nanoparticle enables efficient endosomal escape and cancer treatment. Nano Research, 25(10), 9160-9168.
DOI
2022 Irfan, M., Shahid, A. L., Ahmad, M., Iqbal, W., Elavarasan, R. M., Ren, S., & Hussain, A. (2022). Assessment of public intention to get vaccination against COVID-19: Evidence from a developing country. Journal of Evaluation in Clinical Practice, 28(1), 63-73.
DOI
2022 Li, C., Yang, T., Weng, Y., Zhang, M., Zhao, D., Guo, S., . . . Huang, Y. (2022). Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioactive Materials, 9, 590-601.
DOI
2022 Xu, M., Mao, C., Chen, H., Liu, L., Wang, Y., Hussain, A., . . . Cao, F. (2022). Osteopontin targeted theranostic nanoprobes for laser-induced synergistic regression of vulnerable atherosclerotic plaques. Acta Pharmaceutica Sinica B, 12(4), 2014-2028.
DOI
2022 Hu, B., Li, B., Li, K., Liu, Y., Li, C., Zheng, L., . . . Huang, Y. (2022). Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia. Science Advances, 8(7, article no. eabm1418), 1-18.
DOI
2022 Ullah, A., Chen, G., Yibang, Z., Hussain, A., Shafiq, M., Raza, F., . . . Qi, X. (2022). A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis. Biomaterials Science, 10(10), 2650-2664.
DOI
2021 Li, C., Zhou, J., Wu, Y., Dong, Y., Du, L., Yang, T., . . . Huang, Y. (2021). Core role of hydrophobic core of polymeric nanomicelle in edosomal escape of siRNA. Nano Letters, 21(8), 3680-3689.
DOI
2021 Li, K., Zhang, Y., Hussain, A., Weng, Y., & Huang, Y. (2021). Progress of photodynamic and RNAi combination therapy in cancer treatment. ACS Biomaterials Science and Engineering, 7(9), 4420-4429.
DOI
2021 Ullah, A., Chen, G., Hussain, A., Khan, H., Abbas, A., Zhou, Z., . . . Liu, D. (2021). Cyclam-modified polyethyleneimine for simultaneous tgfβ sirna delivery and cxcr4 inhibition for the treatment of ccl₄ induced liver fibrosis. International Journal of Nanomedicine, 16, 4451-4470.
DOI
2021 Guo, S., Li, K., Hu, B., Li, C., Zhang, M., Hussain, A., . . . Huang, Y. (2021). Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment. Exploration, 1(1), 35-49.
DOI
2019 Khan, M. T., Junaid, M., Mao, X., Wang, Y., Hussain, A., Malik, S. I., & Wei, D. Q. (2019). Pyrazinamide resistance and mutations L19R, R140H, and E144K in Pyrazinamidase of Mycobacterium tuberculosis. Journal of Cellular Biochemistry, 120(5), 7154-7166.
DOI
2019 Hussain, A., & Guo, S. (2019). NIR-triggered release of DOX from sophorolipid-coated mesoporous carbon nanoparticles with the phase-change material 1-tetradecanol to treat MCF-7/ADR cells. Journal of Materials Chemistry B, 7(6), 974-985.
DOI
2017 Huang, S., Liu, J., Zhu, H., Hussain, A., Liu, Q., Li, J., . . . Guo, S. (2017). PEGylated doxorubicin micelles loaded with curcumin exerting synergic effects on multidrug resistant tumor cells. Journal of Nanoscience and Nanotechnology, 17(5), 2873-2880.
DOI
2017 Zhang, Z., Wang, Y., Xu, S., Yu, Y., Hussain, A., Shen, Y., & Guo, S. (2017). Photothermal gold nanocages filled with temperature sensitive tetradecanol and encapsulated with glutathione responsive polycurcumin for controlled DOX delivery to maximize anti-MDR tumor effects. Journal of Materials Chemistry B, 5(27), 5464-5472.
DOI
2017 Zhu, H., Wang, Y., Hussain, A., Zhang, Z., Shen, Y., & Guo, S. (2017). Nanodiamond mediated co-delivery of doxorubicin and malaridine to maximize synergistic anti-tumor effects on multi-drug resistant MCF-7/ADR cells. Journal of Materials Chemistry B, 5(19), 3531-3540.
DOI
2016 Ullah, F., Ayaz, M., Sadiq, A., Hussain, A., Ahmad, S., Imran, M., & Zeb, A. (2016). Phenolic, flavonoid contents, anticholinesterase and antioxidant evaluation of Iris germanica var; florentina. Natural Product Research, 30(12), 1440-1444.
DOI

Date Role Research Topic Program Degree Type Student Load Student Name
2024 Co-Supervisor - Doctor of Philosophy Doctorate Full Time Dan Yan

Connect With Me

External Profiles

Other Links